Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olvi-Vec + Chemotherapy + ICI vs Docetaxel in Advanced NSCLC (VIRO-25)
NCT06463665Phase 2Recruiting
- Sponsor
- Genelux Corporation
- Start
- Sep 2024
- Primary completion
- Feb 2027
- Modality
- Prophylactic Vaccines, Oncolytic Viruses, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of olvimulogene nanivacirepvec in non-small cell lung cancer (NSCLC), sponsored by Genelux Corporation. Started Sep 2024; status: recruiting.
02
Drugs
olvimulogene nanivacirepvec
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06463665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06463665.